Provided by Tiger Trade Technology Pte. Ltd.

iShares MSCI Hong Kong ETF

23.24
-0.1100-0.47%
Post-market: 23.240.00000.00%16:10 EDT
Volume:2.33M
Turnover:54.05M
Market Cap:1.28B
PE:15.90
High:23.27
Open:23.20
Low:23.18
Close:23.35
52wk High:24.66
52wk Low:20.60
Shares:54.90M
Float Shares:54.90M
Volume Ratio:1.01
T/O Rate:4.24%
Dividend:1.04
Dividend Rate:4.46%
EPS(TTM):1.46
EPS(LYR):5.66
ROE:34.64%
ROA:2.14%
PB:1.64
PE(LYR):4.10

Loading ...

Chen Wei Expands Stake in Bar Pacific with HK$20,700 Share Purchase

Deep News
·
Yesterday

Chairman and Executive Director Li Guoxing Increases Stake in Mei Ah Entertainment with 400,000 Share Purchase

Deep News
·
Yesterday

Hong Kong Finance Chief Highlights AI's Growing Role in Boosting Economy and Capital Markets

Stock News
·
Yesterday

China New Town Sets September Payout for Interim Dividend

Deep News
·
Aug 23

CLSA Cuts China Telecom Target Price to HK$5.2, Keeps 'Outperform' Rating

Deep News
·
Aug 23

Morgan Stanley Maintains Overweight on Swire Properties, Cuts Target Price to HK$28

Deep News
·
Aug 23

Morgan Stanley Trims China Resources Beer Target to HK$30, Maintains Overweight Stance

Deep News
·
Aug 23

UBS Raises HKEX Price Target to HK$450, Maintains Neutral Stance

Deep News
·
Aug 23

UBS Raises ND Paper Target Price to HK$11.82, Keeps 'Buy' Rating

Deep News
·
Aug 23

Morgan Stanley Raises BOC Hong Kong Target Price to HK$44.2, Maintains Underweight Rating

Deep News
·
Aug 23

UBS trims AIA target price to HK$102, maintaining "Buy" rating

Deep News
·
Aug 23

Morgan Stanley Lifts Pharmaron Target Price to HK$35.60, Maintains Overweight Rating

Deep News
·
Aug 23

AAC TECH Rating Maintained as Price Target Lifted to HK$52

Deep News
·
Aug 23

Goldman Sachs Lifts NetEase Price Target to HK$263, Maintains Buy Rating

Deep News
·
Aug 23

BofA Securities Lifts CSPC Pharma Target Price to HK$8.6 While Maintaining Underperform Rating

Deep News
·
Aug 23

Morgan Stanley Trims HYSAN DEV Target Price to HK$19, Keeps "Market Perform" Rating

Deep News
·
Aug 23

Citi Raises Keymed Bio Target Price to HK$97.5, Keeps Buy/High Risk Call

Deep News
·
Aug 23

BofA Securities Adjusts Fuyao Glass Price Target While Retaining Buy Stance

Deep News
·
Aug 23

Citi Trims CHINA OVS PPT Price Target to HK$4.5, Keeps 'Buy' Rating

Deep News
·
Aug 23

CITIC Securities Initiates Coverage on SHOUGANG LANZA with Buy Rating and HK$44 Target Price

Deep News
·
Aug 23